Sphingolipids: Key regulators of apoptosis and pivotal players in cancer drug resistance

International Journal of Molecular Sciences

Volumn 15, Issue 3, 2014, Pages 4356-4392

  Giussani, Paola ^a   Tringali, Cristina ^a   Riboni, Laura ^a   Viani, Paola ^a   Venerando, Bruno ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Ceramide; Gangliosides; Globosides; Sialidases; Sphingolipids; Sphingosine 1P

Indexed keywords

CERAMIDASE; CERAMIDE 1 PHOSPHATE; CERAMIDE KINASE; CERAMIDE SYNTHASE; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DIACYLGLYCEROL; FAS ANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; GANGLIOSIDE; GLOBOTETRAOSYLCERAMIDE SYNTHASE; GLOBOTRIAOSYLCERAMIDE SYNTHASE; GLUCOSYLCERAMIDASE; GLYCOSPHINGOLIPID; LACTOSYLCERAMIDE; PALMITOYL COENZYME A; PEPTIDES AND PROTEINS; PHOSPHATIDYLCHOLINE; PROTEIN BCL 2; PROTEIN P53; SPHINGOLIPID; SPHINGOMYELIN; SPHINGOMYELIN SYNTHASE; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE KINASE 1; SPHINGOSINE KINASE 2; SPHINOSINE KINASE; SPINGOMYELINASE; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTINEOPLASTIC AGENT;

APOPTOSIS; CELL ADHESION; CELL CYCLE PROGRESSION; CELL DEATH; CELL GROWTH; CELL MOTILITY; CELL SURVIVAL; CYTOTOXICITY; EMBRYO DEVELOPMENT; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GLYCOSYLATION; HUMAN; NEOPLASM; NONHUMAN; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; VASCULARIZATION; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; NEOPLASMS; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG RESISTANCE, NEOPLASM; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; SIGNAL TRANSDUCTION; SPHINGOLIPIDS;

EID: 84896453676     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms15034356     Document Type: Review

References (246)

1. Longley, D. B.; Johnston, P. G. Molecular mechanisms of drug resistance. J. Pathol. 2005, 205, 275-292.
2. Gottesman, M. M.; Fojo, T.; Bates, S. E. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2, 48-58.
3. Borst, P.; Elferink, R. O. Mammalian ABC transporters in health and disease. Annu. Rev. Biochem. 2002, 71, 537-592.
4. Debatin, K. M.; Krammer, P. H. Death receptors in chemotherapy and cancer. Oncogene 2004, 23, 2950-2966.
5. Valent, P.; Bonnet, D.; de Maria, R.; Lapidot, T.; Copland, M.; Melo, J. V.; Chomienne, C.; Ishikawa, F.; Schuringa, J. J.; Stassi, G.; et al. Cancer stem cell definitions and terminology: The devil is in the details. Nat. Rev. Cancer 2012, 12, 767-775.
6. Lowe, S. W.; Cepero, E.; Evan, G. Intrinsic tumour suppression. Nature 2004, 432, 307-315.
7. Hannun, Y. A.; Obeid, L. M. Principles of bioactive lipid signalling: Lessons from sphingolipids. Nat. Rev. Mol. Cell Biol. 2008, 9, 139-150.
8. Ryland, L. K.; Fox, T. E.; Liu, X.; Loughran, T. P.; Kester, M. Dysregulation of sphingolipid metabolism in cancer. Cancer Biol. Ther. 2011, 11, 138-149.
9. Maurer, B. J.; Metelitsa, L. S.; Seeger, R. C.; Cabot, M. C.; Reynolds, C. P. Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)-retinamide in neuroblastoma cell lines. J. Natl. Cancer Inst. 1999, 91, 1138-1146.
10. Cuvillier, O.; Pirianov, G.; Kleuser, B.; Vanek, P. G.; Coso, O. A.; Gutkind, S.; Spiegel, S. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 1996, 381, 800-803.
11. Hakomori, S. I. Glycosynaptic microdomains controlling tumor cell phenotype through alteration of cell growth, adhesion, and motility. FEBS Lett. 2010, 584, 1901-1906.
12. Gault, C. R.; Obeid, L. M.; Hannun, Y. A. An overview of sphingolipid metabolism: From synthesis to breakdown. Adv. Exp. Med. Biol. 2010, 688, 1-23.
13. Tettamanti, G.; Bassi, R.; Viani, P.; Riboni, L. Salvage pathways in glycosphingolipid metabolism. Biochimie 2003, 85, 423-437.
14. Levy, M.; Futerman, A. H. Mammalian ceramide synthases. IUBMB Life 2010, 62, 347-356.
15. Pewzner-Jung, Y.; Ben-Dor, S.; Futerman, A. H. When do Lasses (longevity assurance genes) become CerS (ceramide synthases)?: Insights into the regulation of ceramide synthesis. J. Biol. Chem. 2006, 281, 25001-25005.
16. Michel, C.; van Echten-Deckert, G. Conversion of dihydroceramide to ceramide occurs at the cytosolic face of the endoplasmic reticulum. FEBS Lett. 1997, 416, 153-155.
17. Bornancin, F. Ceramide kinase: The first decade. Cell Signal. 2011, 23, 999-1008.
18. Huitema, K.; van den Dikkenberg, J.; Brouwers, J. F.; Holthuis, J. C. Identification of a family of animal sphingomyelin synthases. EMBO J. 2004, 23, 33-44.
19. Riboni, L.; Giussani, P.; Viani, P. Sphingolipid transport. Adv. Exp. Med. Biol. 2010, 688, 24-45.
20. Jeckel, D.; Karrenbauer, A.; Burger, K. N.; van Meer, G.; Wieland, F. Glucosylceramide is synthesized at the cytosolic surface of various Golgi subfractions. J. Cell Biol. 1992, 117, 259-267.
21. Ichikawa, S.; Hirabayashi, Y. Glucosylceramide synthase and glycosphingolipid synthesis. Trends Cell Biol. 1998, 8, 198-202.
22. Degroote, S.; Wolthoorn, J.; van Meer, G. The cell biology of glycosphingolipids. Semin. Cell Dev. Biol. 2004, 15, 375-387.
23. Durrant, L. G.; Noble, P.; Spendlove, I. Immunology in the clinic review series; focus on cancer: Glycolipids as targets for tumour immunotherapy. Clin. Exp. Immunol. 2012, 167, 206-215.
24. Tettamanti, G. Ganglioside/glycosphingolipid turnover: New concepts. Glycoconj. J. 2004, 20, 301-317.
25. Papini, N.; Anastasia, L.; Tringali, C.; Croci, G.; Bresciani, R.; Yamaguchi, K.; Miyagi, T.; Preti, A.; Prinetti, A.; Prioni, S.; et al. The plasma membrane-associated sialidase MmNEU3 modifies the ganglioside pattern of adjacent cells supporting its involvement in cell-to-cell interactions. J. Biol. Chem. 2004, 279, 16989-16995.
26. Ledeen, R.; Wu, G. New findings on nuclear gangliosides: Overview on metabolism and function. J. Neurochem. 2011, 116, 714-720.
27. Hasegawa, T.; Sugeno, N.; Takeda, A.; Matsuzaki-Kobayashi, M.; Kikuchi, A.; Furukawa, K.; Miyagi, T.; Itoyama, Y. Role of Neu4L sialidase and its substrate ganglioside GD3 in neuronal apoptosis induced by catechol metabolites. FEBS Lett. 2007, 581, 406-412.
28. Tringali, C.; Papini, N.; Fusi, P.; Croci, G.; Borsani, G.; Preti, A.; Tortora, P.; Tettamanti, G.; Venerando, B.; Monti, E. Properties of recombinant human cytosolic sialidase HsNEU2. The enzyme hydrolyzes monomerically dispersed GM1 ganglioside molecules. J. Biol. Chem. 2004, 279, 3169-3179.
29. Marchesini, N.; Hannun, Y. A. Acid and neutral sphingomyelinases: Roles and mechanisms of regulation. Biochem. Cell Biol. 2004, 82, 27-44.
30. Romiti, E.; Vasta, V.; Meacci, E.; Farnararo, M.; Linke, T.; Ferlinz, K.; Sandhoff, K.; Bruni, P. Characterization of sphingomyelinase activity released by thrombin-stimulated platelets. Mol. Cell Biochem. 2000, 205, 75-81.
31. Clarke, C. J.; Wu, B. X.; Hannun, Y. A. The neutral sphingomyelinase family: Identifying biochemical connections. Adv. Enzyme Regul. 2011, 51, 51-58.
32. Duan, R. D. Alkaline sphingomyelinase: An old enzyme with novel implications. Biochim. Biophys. Acta 2006, 1761, 281-291.
33. Mao, C.; Obeid, L. M. Ceramidases: Regulators of cellular responses mediated by ceramide, sphingosine, and sphingosine-1-phosphate. Biochim. Biophys. Acta 2008, 1781, 424-434.
34. Ferlinz, K.; Kopal, G.; Bernardo, K.; Linke, T.; Bar, J.; Breiden, B.; Neumann, U.; Lang, F.; Schuchman, E. H.; Sandhoff, K. Human acid ceramidase: Processing, glycosylation, and lysosomal targeting. J. Biol. Chem. 2001, 276, 35352-35360.
35. Romiti, E.; Meacci, E.; Tani, M.; Nuti, F.; Farnararo, M.; Ito, M.; Bruni, P. Neutral/alkaline and acid ceramidase activities are actively released by murine endothelial cells. Biochem. Biophys. Res. Commun. 2000, 275, 746-751.
36. Hwang, Y. H.; Tani, M.; Nakagawa, T.; Okino, N.; Ito, M. Subcellular localization of human neutral ceramidase expressed in HEK293 cells. Biochem. Biophys. Res. Commun. 2005, 331, 37-42.
37. Mao, C.; Xu, R.; Szulc, Z. M.; Bielawska, A.; Galadari, S. H.; Obeid, L. M. Cloning and characterization of a novel human alkaline ceramidase. A mammalian enzyme that hydrolyzes phytoceramide. J. Biol. Chem. 2001, 276, 26577-26588.
38. Sandhoff, K.; Kolter, T. Topology of glycosphingolipid degradation. Trends Cell Biol. 1996, 6, 98-103.
39. Nava, V. E.; Lacana, E.; Poulton, S.; Liu, H.; Sugiura, M.; Kono, K.; Milstien, S.; Kohama, T.; Spiegel, S. Functional characterization of human sphingosine kinase-1. FEBS Lett. 2000, 473, 81-84.
40. Liu, H.; Chakravarty, D.; Maceyka, M.; Milstien, S.; Spiegel, S. Sphingosine kinases: A novel family of lipid kinases. Prog. Nucleic Acid Res. Mol. Biol. 2002, 71, 493-511.
41. Liu, H.; Sugiura, M.; Nava, V. E.; Edsall, L. C.; Kono, K.; Poulton, S.; Milstien, S.; Kohama, T.; Spiegel, S. Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform. J. Biol. Chem. 2000, 275, 19513-19520.
42. Serra, M.; Saba, J. D. Sphingosine 1-phosphate lyase, a key regulator of sphingosine 1-phosphate signaling and function. Adv. Enzyme Regul. 2010, 50, 349-362.
43. Le Stunff, H.; Peterson, C.; Thornton, R.; Milstien, S.; Mandala, S. M.; Spiegel, S. Characterization of murine sphingosine-1-phosphate phosphohydrolase. J. Biol. Chem. 2002, 277, 8920-8927.
44. Le Stunff, H.; Giussani, P.; Maceyka, M.; Lepine, S.; Milstien, S.; Spiegel, S. Recycling of sphingosine is regulated by the concerted actions of sphingosine-1-phosphate phosphohydrolase 1 and sphingosine kinase 2. J. Biol. Chem. 2007, 282, 34372-34380.
45. Pyne, S.; Lee, S. C.; Long, J.; Pyne, N. J. Role of sphingosine kinases and lipid phosphate phosphatases in regulating spatial sphingosine 1-phosphate signalling in health and disease. Cell Signal. 2009, 21, 14-21.
46. Krammer, P. H. CD95(APO-1/Fas)-mediated apoptosis: Live and let die. Adv. Immunol. 1999, 71, 163-210.
47. Schmitz, I.; Kirchhoff, S.; Krammer, P. H. Regulation of death receptor-mediated apoptosis pathways. Int. J. Biochem. Cell Biol. 2000, 32, 1123-1136.
48. Pitti, R. M.; Marsters, S. A.; Lawrence, D. A.; Roy, M.; Kischkel, F. C.; Dowd, P.; Huang, A.; Donahue, C. J.; Sherwood, S. W.; Baldwin, D. T.; et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998, 396, 699-703.
49. Yu, K. Y.; Kwon, B.; Ni, J.; Zhai, Y.; Ebner, R.; Kwon, B. S. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J. Biol. Chem. 1999, 274, 13733-13736.
50. Ashkenazi, A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat. Rev. Cancer 2002, 2, 420-430.
51. Sprick, M. R.; Weigand, M. A.; Rieser, E.; Rauch, C. T.; Juo, P.; Blenis, J.; Krammer, P. H.; Walczak, H. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 2000, 12, 599-609.
52. Kischkel, F. C.; Hellbardt, S.; Behrmann, I.; Germer, M.; Pawlita, M.; Krammer, P. H.; Peter, M. E. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 1995, 14, 5579-5588.
53. Zamzami, N.; Kroemer, G. The mitochondrion in apoptosis: How Pandora's box opens. Nat. Rev. Mol. Cell Biol. 2001, 2, 67-71.
54. Martinou, J. C.; Green, D. R. Breaking the mitochondrial barrier. Nat. Rev. Mol. Cell Biol. 2001, 2, 63-67.
55. Rathmell, J. C.; Thompson, C. B. The central effectors of cell death in the immune system. Annu. Rev. Immunol. 1999, 17, 781-828.
56. Nakano, K.; Vousden, K. H. PUMA, a novel proapoptotic gene, is induced by p53. Mol. Cell 2001, 7, 683-694.
57. Oda, K.; Arakawa, H.; Tanaka, T.; Matsuda, K.; Tanikawa, C.; Mori, T.; Nishimori, H.; Tamai, K.; Tokino, T.; Nakamura, Y.; et al. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 2000, 102, 849-862.
58. Muller, M.; Wilder, S.; Bannasch, D.; Israeli, D.; Lehlbach, K.; Li-Weber, M.; Friedman, S. L.; Galle, P. R.; Stremmel, W.; Oren, M.; et al. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J. Exp. Med. 1998, 188, 2033-2045.
59. Wu, G. S.; Burns, T. F.; McDonald, E. R., 3rd; Jiang, W.; Meng, R.; Krantz, I. D.; Kao, G.; Gan, D. D.; Zhou, J. Y.; Muschel, R.; et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat. Genet. 1997, 17, 141-143.
60. Igney, F. H.; Krammer, P. H. Death and anti-death: Tumour resistance to apoptosis. Nat. Rev. Cancer 2002, 2, 277-288.
61. Holohan, C.; van Schaeybroeck, S.; Longley, D. B.; Johnston, P. G. Cancer drug resistance: An evolving paradigm. Nat. Rev. Cancer 2013, 13, 714-726.
62. Sharma, S. V.; Haber, D. A.; Settleman, J. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat. Rev. Cancer 2010, 10, 241-253.
63. Datta, S. R.; Brunet, A.; Greenberg, M. E. Cellular survival: A play in three Akts. Genes Dev. 1999, 13, 2905-2927.
64. Frisch, S. M.; Screaton, R. A. Anoikis mechanisms. Curr. Opin. Cell Biol. 2001, 13, 555-562.
65. Herr, I.; Debatin, K. M. Cellular stress response and apoptosis in cancer therapy. Blood 2001, 98, 2603-2614.
66. Hannun, Y. A. Functions of ceramide in coordinating cellular responses to stress. Science 1996, 274, 1855-1859.
67. Hannun, Y. A.; Obeid, L. M. The Ceramide-centric universe of lipid-mediated cell regulation: Stress encounters of the lipid kind. J. Biol. Chem. 2002, 277, 25847-25850.
68. Ogretmen, B.; Hannun, Y. A. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat. Rev. Cancer 2004, 4, 604-616.
69. Gouaze-Andersson, V.; Cabot, M. C. Glycosphingolipids and drug resistance. Biochim. Biophys. Acta 2006, 1758, 2096-2103.
70. Reynolds, C. P.; Maurer, B. J.; Kolesnick, R. N. Ceramide synthesis and metabolism as a target for cancer therapy. Cancer Lett. 2004, 206, 169-180.
71. Morad, S. A.; Cabot, M. C. Ceramide-orchestrated signalling in cancer cells. Nat. Rev. Cancer 2013, 13, 51-65.
72. Bose, R.; Verheij, M.; Haimovitz-Friedman, A.; Scotto, K.; Fuks, Z.; Kolesnick, R. Ceramide synthase mediates daunorubicin-induced apoptosis: An alternative mechanism for generating death signals. Cell 1995, 82, 405-414.
73. Gomez del Pulgar, T.; Velasco, G.; Sanchez, C.; Haro, A.; Guzman, M. De novo-synthesized ceramide is involved in cannabinoid-induced apoptosis. Biochem. J. 2002, 363, 183-188.
74. Perry, D. K.; Carton, J.; Shah, A. K.; Meredith, F.; Uhlinger, D. J.; Hannun, Y. A. Serine palmitoyltransferase regulates de novo ceramide generation during etoposide-induced apoptosis. J. Biol. Chem. 2000, 275, 9078-9084.
75. Chalfant, C. E.; Ogretmen, B.; Galadari, S.; Kroesen, B. J.; Pettus, B. J.; Hannun, Y. A. FAS activation induces dephosphorylation of SR proteins; dependence on the de novo generation of ceramide and activation of protein phosphatase 1. J. Biol. Chem. 2001, 276, 44848-44855.
76. Luberto, C.; Hassler, D. F.; Signorelli, P.; Okamoto, Y.; Sawai, H.; Boros, E.; Hazen-Martin, D. J.; Obeid, L. M.; Hannun, Y. A.; Smith, G. K. Inhibition of tumor necrosis factor-induced cell death in MCF7 by a novel inhibitor of neutral sphingomyelinase. J. Biol. Chem. 2002, 277, 41128-41139.
77. Liu, J. J.; Wang, J. Y.; Hertervig, E.; Cheng, Y.; Nilsson, A.; Duan, R. D. Activation of neutral sphingomyelinase participates in ethanol-induced apoptosis in Hep G2 cells. Alcohol. Alcohol. 2000, 35, 569-573.
78. Sorli, S. C.; Colie, S.; Albinet, V.; Dubrac, A.; Touriol, C.; Guilbaud, N.; Bedia, C.; Fabrias, G.; Casas, J.; Segui, B.; et al. The nonlysosomal β-glucosidase GBA2 promotes endoplasmic reticulum stress and impairs tumorigenicity of human melanoma cells. FASEB J. 2013, 27, 489-498.
79. Liu, Y. Y.; Han, T. Y.; Giuliano, A. E.; Cabot, M. C. Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J. 2001, 15, 719-730.
80. Kok, J. W.; Sietsma, H. Sphingolipid metabolism enzymes as targets for anticancer therapy. Curr. Drug Targets 2004, 5, 375-382.
81. Giussani, P.; Bassi, R.; Anelli, V.; Brioschi, L.; de Zen, F.; Riccitelli, E.; Caroli, M.; Campanella, R.; Gaini, S. M.; Viani, P.; et al. Glucosylceramide synthase protects glioblastoma cells against autophagic and apoptotic death induced by temozolomide and Paclitaxel. Cancer Investig. 2012, 30, 27-37.
82. Senchenkov, A.; Litvak, D. A.; Cabot, M. C. Targeting ceramide metabolism-A strategy for overcoming drug resistance. J. Natl. Cancer Inst. 2001, 93, 347-357.
83. Grazide, S.; Terrisse, A. D.; Lerouge, S.; Laurent, G.; Jaffrezou, J. P. Cytoprotective effect of glucosylceramide synthase inhibition against daunorubicin-induced apoptosis in human leukemic cell lines. J. Biol. Chem. 2004, 279, 18256-18261.
84. Owczarek, T. B.; Suchanski, J.; Pula, B.; Kmiecik, A. M.; Chadalski, M.; Jethon, A.; Dziegiel, P.; Ugorski, M. Galactosylceramide affects tumorigenic and metastatic properties of breast cancer cells as an anti-apoptotic molecule. PLoS One 2013, 8, e84191.
85. Itoh, M.; Kitano, T.; Watanabe, M.; Kondo, T.; Yabu, T.; Taguchi, Y.; Iwai, K.; Tashima, M.; Uchiyama, T.; Okazaki, T. Possible role of ceramide as an indicator of chemoresistance: Decrease of the ceramide content via activation of glucosylceramide synthase and sphingomyelin synthase in chemoresistant leukemia. Clin. Cancer Res. 2003, 9, 415-423.
86. Lafont, E.; Milhas, D.; Carpentier, S.; Garcia, V.; Jin, Z. X.; Umehara, H.; Okazaki, T.; Schulze-Osthoff, K.; Levade, T.; Benoist, H.; et al. Caspase-mediated inhibition of sphingomyelin synthesis is involved in FasL-triggered cell death. Cell Death Differ. 2010, 17, 642-654.
87. Separovic, D.; Hanada, K.; Maitah, M. Y.; Nagy, B.; Hang, I.; Tainsky, M. A.; Kraniak, J. M.; Bielawski, J. Sphingomyelin synthase 1 suppresses ceramide production and apoptosis post-photodamage. Biochem. Biophys. Res. Commun. 2007, 358, 196-202.
88. Dolgachev, V.; Farooqui, M. S.; Kulaeva, O. I.; Tainsky, M. A.; Nagy, B.; Hanada, K.; Separovic, D. De novo ceramide accumulation due to inhibition of its conversion to complex sphingolipids in apoptotic photosensitized cells. J. Biol. Chem. 2004, 279, 23238-23249.
89. Barth, B. M.; Cabot, M. C.; Kester, M. Ceramide-based therapeutics for the treatment of cancer. Anti-Cancer Agents Med. Chem. 2011, 11, 911-919.
90. Hanada, K.; Kumagai, K.; Yasuda, S.; Miura, Y.; Kawano, M.; Fukasawa, M.; Nishijima, M. Molecular machinery for non-vesicular trafficking of ceramide. Nature 2003, 426, 803-809.
91. Swanton, C.; Marani, M.; Pardo, O.; Warne, P. H.; Kelly, G.; Sahai, E.; Elustondo, F.; Chang, J.; Temple, J.; Ahmed, A. A.; et al. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 2007, 11, 498-512.
92. Lee, A. J.; Roylance, R.; Sander, J.; Gorman, P.; Endesfelder, D.; Kschischo, M.; Jones, N. P.; East, P.; Nicke, B.; Spassieva, S.; et al. CERT depletion predicts chemotherapy benefit and mediates cytotoxic and polyploid-specific cancer cell death through autophagy induction. J. Pathol. 2012, 226, 482-494.
93. Heering, J.; Weis, N.; Holeiter, M.; Neugart, F.; Staebler, A.; Fehm, T. N.; Bischoff, A.; Schiller, J.; Duss, S.; Schmid, S.; et al. Loss of the ceramide transfer protein augments EGF receptor signaling in breast cancer. Cancer Res. 2012, 72, 2855-2866.
94. Van Brocklyn, J. R. Sphingolipid signaling pathways as potential therapeutic targets in gliomas. Mini Rev. Med. Chem. 2007, 7, 984-990.
95. Hara, S.; Nakashima, S.; Kiyono, T.; Sawada, M.; Yoshimura, S.; Iwama, T.; Sakai, N. Ceramide triggers caspase activation during gamma-radiation-induced apoptosis of human glioma cells lacking functional p53. Oncol. Rep. 2004, 12, 119-123.
96. Hara, S.; Nakashima, S.; Kiyono, T.; Sawada, M.; Yoshimura, S.; Iwama, T.; Banno, Y.; Shinoda, J.; Sakai, N. p53-Independent ceramide formation in human glioma cells during gamma-radiation-induced apoptosis. Cell Death Differ. 2004, 11, 853-861.
97. Velasco, G.; Galve-Roperh, I.; Sanchez, C.; Blazquez, C.; Haro, A.; Guzman, M. Cannabinoids and ceramide: Two lipids acting hand-by-hand. Life Sci. 2005, 77, 1723-1731.
98. Viani, P.; Giussani, P.; Brioschi, L.; Bassi, R.; Anelli, V.; Tettamanti, G.; Riboni, L. Ceramide in nitric oxide inhibition of glioma cell growth. Evidence for the involvement of ceramide traffic. J. Biol. Chem. 2003, 278, 9592-9601.
99. Gramatzki, D.; Herrmann, C.; Happold, C.; Becker, K. A.; Gulbins, E.; Weller, M.; Tabatabai, G. Glioma cell death induced by irradiation or alkylating agent chemotherapy is independent of the intrinsic ceramide pathway. PLoS One 2013, 8, e63527.
100. Barcelo-Coblijn, G.; Martin, M. L.; de Almeida, R. F.; Noguera-Salva, M. A.; Marcilla-Etxenike, A.; Guardiola-Serrano, F.; Luth, A.; Kleuser, B.; Halver, J. E.; Escriba, P. V. Sphingomyelin and sphingomyelin synthase (SMS) in the malignant transformation of glioma cells and in 2-hydroxyoleic acid therapy. Proc. Natl. Acad. Sci. USA 2011, 108, 19569-19574.
101. Giussani, P.; Colleoni, T.; Brioschi, L.; Bassi, R.; Hanada, K.; Tettamanti, G.; Riboni, L.; Viani, P. Ceramide traffic in C6 glioma cells: Evidence for CERT-dependent and independent transport from ER to the Golgi apparatus. Biochim. Biophys. Acta 2008, 1781, 40-51.
102. Giussani, P.; Maceyka, M.; le Stunff, H.; Mikami, A.; Lepine, S.; Wang, E.; Kelly, S.; Merrill, A. H., Jr.; Milstien, S.; Spiegel, S. Sphingosine-1-phosphate phosphohydrolase regulates endoplasmic reticulum-to-golgi trafficking of ceramide. Mol. Cell. Biol. 2006, 26, 5055-5069.
103. Veret, J.; Coant, N.; Gorshkova, I. A.; Giussani, P.; Fradet, M.; Riccitelli, E.; Skobeleva, A.; Goya, J.; Kassis, N.; Natarajan, V.; et al. Role of palmitate-induced sphingoid base-1-phosphate biosynthesis in INS-1 β-cell survival. Biochim. Biophys. Acta 2013, 1831, 251-262.
104. Sami, A.; Karsy, M. Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: Novel therapeutic agents and advances in understanding. Tumour Biol. 2013, 34, 1991-2002.
105. Giussani, P.; Brioschi, L.; Bassi, R.; Riboni, L.; Viani, P. Phosphatidylinositol 3-kinase/AKT pathway regulates the endoplasmic reticulum to golgi traffic of ceramide in glioma cells: A link between lipid signaling pathways involved in the control of cell survival. J. Biol. Chem. 2009, 284, 5088-5096.
106. Hannun, Y. A.; Obeid, L. M. Many ceramides. J. Biol. Chem. 2011, 286, 27855-27862.
107. Dbaibo, G. S.; Pushkareva, M. Y.; Jayadev, S.; Schwarz, J. K.; Horowitz, J. M.; Obeid, L. M.; Hannun, Y. A. Retinoblastoma gene product as a downstream target for a ceramide-dependent pathway of growth arrest. Proc. Natl. Acad. Sci. USA 1995, 92, 1347-1351.
108. Chalfant, C. E.; Rathman, K.; Pinkerman, R. L.; Wood, R. E.; Obeid, L. M.; Ogretmen, B.; Hannun, Y. A. De novo ceramide regulates the alternative splicing of caspase 9 and Bcl-x in A549 lung adenocarcinoma cells. Dependence on protein phosphatase-1. J. Biol. Chem. 2002, 277, 12587-12595.
109. Ruvolo, P. P.; Deng, X.; Ito, T.; Carr, B. K.; May, W. S. Ceramide induces Bcl2 dephosphorylation via a mechanism involving mitochondrial PP2A. J. Biol. Chem. 1999, 274, 20296-20300.
110. Young, M. M.; Kester, M.; Wang, H. G. Sphingolipids: Regulators of crosstalk between apoptosis and autophagy. J. Lipid Res. 2013, 54, 5-19.
111. Riboni, L.; Viani, P.; Bassi, R.; Stabilini, A.; Tettamanti, G. Biomodulatory role of ceramide in basic fibroblast growth factor-induced proliferation of cerebellar astrocytes in primary culture. Glia 2000, 32, 137-145.
112. Meloche, S.; Pouyssegur, J. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1-to S-phase transition. Oncogene 2007, 26, 3227-3239.
113. Mebratu, Y.; Tesfaigzi, Y. How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer? Cell Cycle 2009, 8, 1168-1175.
114. Chalfant, C. E.; Szulc, Z.; Roddy, P.; Bielawska, A.; Hannun, Y. A. The structural requirements for ceramide activation of serine-threonine protein phosphatases. J. Lipid Res. 2004, 45, 496-506.
115. Lee, W. J.; Kim, D. U.; Lee, M. Y.; Choi, K. Y. Identification of proteins interacting with the catalytic subunit of PP2A by proteomics. Proteomics 2007, 7, 206-214.
116. Adams, D. G.; Coffee, R. L., Jr.; Zhang, H.; Pelech, S.; Strack, S.; Wadzinski, B. E. Positive regulation of Raf1-MEK1/2-ERK1/2 signaling by protein serine/threonine phosphatase 2A holoenzymes. J. Biol. Chem. 2005, 280, 42644-42654.
117. Lahiri, S.; Futerman, A. H. The metabolism and function of sphingolipids and glycosphingolipids. Cell. Mol. Life Sci. 2007, 64, 2270-2284.
118. Bollinger, C. R.; Teichgraber, V.; Gulbins, E. Ceramide-enriched membrane domains. Biochim. Biophys. Acta 2005, 1746, 284-294.
119. Grassme, H.; Cremesti, A.; Kolesnick, R.; Gulbins, E. Ceramide-mediated clustering is required for CD95-DISC formation. Oncogene 2003, 22, 5457-5470.
120. Matsko, C. M.; Hunter, O. C.; Rabinowich, H.; Lotze, M. T.; Amoscato, A. A. Mitochondrial lipid alterations during Fas-and radiation-induced apoptosis. Biochem. Biophys. Res. Commun. 2001, 287, 1112-1120.
121. Birbes, H.; El Bawab, S.; Hannun, Y. A.; Obeid, L. M. Selective hydrolysis of a mitochondrial pool of sphingomyelin induces apoptosis. FASEB J. 2001, 15, 2669-2679.
122. Siskind, L. J.; Kolesnick, R. N.; Colombini, M. Ceramide channels increase the permeability of the mitochondrial outer membrane to small proteins. J. Biol. Chem. 2002, 277, 26796-26803.
123. Sawada, M.; Nakashima, S.; Banno, Y.; Yamakawa, H.; Takenaka, K.; Shinoda, J.; Nishimura, Y.; Sakai, N.; Nozawa, Y. Influence of Bax or Bcl-2 overexpression on the ceramide-dependent apoptotic pathway in glioma cells. Oncogene 2000, 19, 3508-3520.
124. Birbes, H.; Luberto, C.; Hsu, Y. T.; El Bawab, S.; Hannun, Y. A.; Obeid, L. M. A mitochondrial pool of sphingomyelin is involved in TNFα-induced Bax translocation to mitochondria. Biochem. J. 2005, 386, 445-451.
125. Von Haefen, C.; Wieder, T.; Gillissen, B.; Starck, L.; Graupner, V.; Dorken, B.; Daniel, P. T. Ceramide induces mitochondrial activation and apoptosis via a Bax-dependent pathway in human carcinoma cells. Oncogene 2002, 21, 4009-4019.
126. Kim, H. J.; Mun, J. Y.; Chun, Y. J.; Choi, K. H.; Kim, M. Y. Bax-dependent apoptosis induced by ceramide in HL-60 cells. FEBS Lett. 2001, 505, 264-268.
127. Chipuk, J. E.; McStay, G. P.; Bharti, A.; Kuwana, T.; Clarke, C. J.; Siskind, L. J.; Obeid, L. M.; Green, D. R. Sphingolipid metabolism cooperates with BAK and BAX to promote the mitochondrial pathway of apoptosis. Cell 2012, 148, 988-1000.
128. Young, M.; Wheaton, B. The impact of neighborhood composition on work-family conflict and distress. J. Health Soc. Behav. 2013, 54, 481-497.
129. Xin, M.; Deng, X. Protein phosphatase 2A enhances the proapoptotic function of Bax through dephosphorylation. J. Biol. Chem. 2006, 281, 18859-18867.
130. Bryan, L.; Kordula, T.; Spiegel, S.; Milstien, S. Regulation and functions of sphingosine kinases in the brain. Biochim. Biophys. Acta 2008, 1781, 459-466.
131. Shida, D.; Takabe, K.; Kapitonov, D.; Milstien, S.; Spiegel, S. Targeting SphK1 as a new strategy against cancer. Curr. Drug Targets 2008, 9, 662-673.
132. Pyne, N. J.; Pyne, S. Sphingosine 1-phosphate and cancer. Nat. Rev. Cancer 2010, 10, 489-503.
133. Pchejetski, D.; Golzio, M.; Bonhoure, E.; Calvet, C.; Doumerc, N.; Garcia, V.; Mazerolles, C.; Rischmann, P.; Teissie, J.; Malavaud, B.; et al. Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models. Cancer Res. 2005, 65, 11667-11675.
134. Bektas, M.; Jolly, P. S.; Muller, C.; Eberle, J.; Spiegel, S.; Geilen, C. C. Sphingosine kinase activity counteracts ceramide-mediated cell death in human melanoma cells: Role of Bcl-2 expression. Oncogene 2005, 24, 178-187.
135. Sukocheva, O.; Wang, L.; Verrier, E.; Vadas, M. A.; Xia, P. Restoring endocrine response in breast cancer cells by inhibition of the sphingosine kinase-1 signaling pathway. Endocrinology 2009, 150, 4484-4492.
136. Taha, T. A.; Kitatani, K.; Bielawski, J.; Cho, W.; Hannun, Y. A.; Obeid, L. M. Tumor necrosis factor induces the loss of sphingosine kinase-1 by a cathepsin B-dependent mechanism. J. Biol. Chem. 2005, 280, 17196-17202.
137. Okada, T.; Ding, G.; Sonoda, H.; Kajimoto, T.; Haga, Y.; Khosrowbeygi, A.; Gao, S.; Miwa, N.; Jahangeer, S.; Nakamura, S. Involvement of N-terminal-extended form of sphingosine kinase 2 in serum-dependent regulation of cell proliferation and apoptosis. J. Biol. Chem. 2005, 280, 36318-36325.
138. Liu, H.; Toman, R. E.; Goparaju, S. K.; Maceyka, M.; Nava, V. E.; Sankala, H.; Payne, S. G.; Bektas, M.; Ishii, I.; Chun, J.; et al. Sphingosine kinase type 2 is a putative BH3-only protein that induces apoptosis. J. Biol. Chem. 2003, 278, 40330-40336.
139. Igarashi, N.; Okada, T.; Hayashi, S.; Fujita, T.; Jahangeer, S.; Nakamura, S. Sphingosine kinase 2 is a nuclear protein and inhibits DNA synthesis. J. Biol. Chem. 2003, 278, 46832-46839.
140. Van Brocklyn, J. R.; Jackson, C. A.; Pearl, D. K.; Kotur, M. S.; Snyder, P. J.; Prior, T. W. Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: Roles of sphingosine kinase isoforms in growth of glioblastoma cell lines. J. Neuropathol. Exp. Neurol. 2005, 64, 695-705.
141. Min, J.; Mesika, A.; Sivaguru, M.; van Veldhoven, P. P.; Alexander, H.; Futerman, A. H.; Alexander, S. (Dihydro)ceramide synthase 1 regulated sensitivity to cisplatin is associated with the activation of p38 mitogen-activated protein kinase and is abrogated by sphingosine kinase 1. Mol. Cancer Res. 2007, 5, 801-812.
142. Zhang, H.; Li, W.; Sun, S.; Yu, S.; Zhang, M.; Zou, F. Inhibition of sphingosine kinase 1 suppresses proliferation of glioma cells under hypoxia by attenuating activity of extracellular signal-regulated kinase. Cell Prolif. 2012, 45, 167-175.
143. Edsall, L. C.; Cuvillier, O.; Twitty, S.; Spiegel, S.; Milstien, S. Sphingosine kinase expression regulates apoptosis and caspase activation in PC12 cells. J. Neurochem. 2001, 76, 1573-1584.
144. Riccitelli, E.; Giussani, P.; di Vito, C.; Condomitti, G.; Tringali, C.; Caroli, M.; Galli, R.; Viani, P.; Riboni, L. Extracellular sphingosine-1-phosphate: A novel actor in human glioblastoma stem cell survival. PLoS One 2013, 8, e68229.
145. Maceyka, M.; Sankala, H.; Hait, N. C.; le Stunff, H.; Liu, H.; Toman, R.; Collier, C.; Zhang, M.; Satin, L. S.; Merrill, A. H., Jr.; et al. SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism. J. Biol. Chem. 2005, 280, 37118-37129.
146. Payne, S. G.; Milstien, S.; Spiegel, S. Sphingosine-1-phosphate: Dual messenger functions. FEBS Lett. 2002, 531, 54-57.
147. Bassi, R.; Anelli, V.; Giussani, P.; Tettamanti, G.; Viani, P.; Riboni, L. Sphingosine-1-phosphate is released by cerebellar astrocytes in response to bFGF and induces astrocyte proliferation through Gi-protein-coupled receptors. Glia 2006, 53, 621-630.
148. Le Stunff, H.; Mikami, A.; Giussani, P.; Hobson, J. P.; Jolly, P. S.; Milstien, S.; Spiegel, S. Role of sphingosine-1-phosphate phosphatase 1 in epidermal growth factor-induced chemotaxis. J. Biol. Chem. 2004, 279, 34290-34297.
149. Igarashi, J.; Bernier, S. G.; Michel, T. Sphingosine 1-phosphate and activation of endothelial nitric-oxide synthase. differential regulation of Akt and MAP kinase pathways by EDG and bradykinin receptors in vascular endothelial cells. J. Biol. Chem. 2001, 276, 12420-12426.
150. Siehler, S.; Wang, Y.; Fan, X.; Windh, R. T.; Manning, D. R. Sphingosine 1-phosphate activates nuclear factor-kappa B through Edg receptors. Activation through Edg-3 and Edg-5, but not Edg-1, in human embryonic kidney 293 cells. J. Biol. Chem. 2001, 276, 48733-48739.
151. Zondag, G. C.; Postma, F. R.; Etten, I. V.; Verlaan, I.; Moolenaar, W. H. Sphingosine 1-phosphate signalling through the G-protein-coupled receptor Edg-1. Biochem. J. 1998, 330, 605-609.
152. 2+ mobilization independently of G-protein-coupled receptors. FEBS Lett. 2003, 554, 443-449.
153. Hait, N. C.; Allegood, J.; Maceyka, M.; Strub, G. M.; Harikumar, K. B.; Singh, S. K.; Luo, C.; Marmorstein, R.; Kordula, T.; Milstien, S.; et al. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science 2009, 325, 1254-1257.
154. French, K. J.; Schrecengost, R. S.; Lee, B. D.; Zhuang, Y.; Smith, S. N.; Eberly, J. L.; Yun, J. K.; Smith, C. D. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res. 2003, 63, 5962-5969.
155. Sweeney, E. A.; Sakakura, C.; Shirahama, T.; Masamune, A.; Ohta, H.; Hakomori, S.; Igarashi, Y. Sphingosine and its methylated derivative N, N-dimethylsphingosine (DMS) induce apoptosis in a variety of human cancer cell lines. Int. J. Cancer. J. Int. Cancer 1996, 66, 358-366.
156. Shirahama, T.; Sweeney, E. A.; Sakakura, C.; Singhal, A. K.; Nishiyama, K.; Akiyama, S.; Hakomori, S.; Igarashi, Y. In vitro and in vivo induction of apoptosis by sphingosine and N, N-dimethylsphingosine in human epidermoid carcinoma KB-3-1 and its multidrug-resistant cells. Clin. Cancer Res. 1997, 3, 257-264.
157. Cuvillier, O.; Levade, T. Sphingosine 1-phosphate antagonizes apoptosis of human leukemia cells by inhibiting release of cytochrome c and Smac/DIABLO from mitochondria. Blood 2001, 98, 2828-2836.
158. Adan-Gokbulut, A.; Kartal-Yandim, M.; Iskender, G.; Baran, Y. Novel agents targeting bioactive sphingolipids for the treatment of cancer. Curr. Med. Chem. 2013, 20, 108-122.
159. Dickson, M. A.; Carvajal, R. D.; Merrill, A. H., Jr.; Gonen, M.; Cane, L. M.; Schwartz, G. K. A phase I clinical trial of safingol in combination with cisplatin in advanced solid tumors. Clin. Cancer Res. 2011, 17, 2484-2492.
160. Kapitonov, D.; Allegood, J. C.; Mitchell, C.; Hait, N. C.; Almenara, J. A.; Adams, J. K.; Zipkin, R. E.; Dent, P.; Kordula, T.; Milstien, S.; et al. Targeting sphingosine kinase 1 inhibits Akt signaling, induces apoptosis, and suppresses growth of human glioblastoma cells and xenografts. Cancer Res. 2009, 69, 6915-6923.
161. Beljanski, V.; Knaak, C.; Smith, C. D. A novel sphingosine kinase inhibitor induces autophagy in tumor cells. J. Pharmacol. Exp. Ther. 2010, 333, 454-464.
162. Matsuoka, Y.; Nagahara, Y.; Ikekita, M.; Shinomiya, T. A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells. Br. J. Pharmacol. 2003, 138, 1303-1312.
163. Azuma, H.; Takahara, S.; Horie, S.; Muto, S.; Otsuki, Y.; Katsuoka, Y. Induction of apoptosis in human bladder cancer cells in vitro and in vivo caused by FTY720 treatment. J. Urol. 2003, 169, 2372-2377.
164. Sonoda, Y.; Yamamoto, D.; Sakurai, S.; Hasegawa, M.; Aizu-Yokota, E.; Momoi, T.; Kasahara, T. FTY720, a novel immunosuppressive agent, induces apoptosis in human glioma cells. Biochem. Biophys. Res. Commun. 2001, 281, 282-288.
165. Wang, J. D.; Takahara, S.; Nonomura, N.; Ichimaru, N.; Toki, K.; Azuma, H.; Matsumiya, K.; Okuyama, A.; Suzuki, S. Early induction of apoptosis in androgen-independent prostate cancer cell line by FTY720 requires caspase-3 activation. Prostate 1999, 40, 50-55.
166. Yasui, H.; Hideshima, T.; Raje, N.; Roccaro, A. M.; Shiraishi, N.; Kumar, S.; Hamasaki, M.; Ishitsuka, K.; Tai, Y. T.; Podar, K.; et al. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance. Cancer Res. 2005, 65, 7478-7484.
167. Azuma, H.; Takahara, S.; Ichimaru, N.; Wang, J. D.; Itoh, Y.; Otsuki, Y.; Morimoto, J.; Fukui, R.; Hoshiga, M.; Ishihara, T.; et al. Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models. Cancer Res. 2002, 62, 1410-1419.
168. Lepine, S.; Allegood, J. C.; Edmonds, Y.; Milstien, S.; Spiegel, S. Autophagy induced by deficiency of sphingosine-1-phosphate phosphohydrolase 1 is switched to apoptosis by calpain-mediated autophagy-related gene 5 (Atg5) cleavage. J. Biol. Chem. 2011, 286, 44380-44390.
169. Young, M. M.; Takahashi, Y.; Khan, O.; Park, S.; Hori, T.; Yun, J.; Sharma, A. K.; Amin, S.; Hu, C. D.; Zhang, J.; et al. Autophagosomal membrane serves as platform for intracellular death-inducing signaling complex (iDISC)-mediated caspase-8 activation and apoptosis. J. Biol. Chem. 2012, 287, 12455-12468.
170. Scarlatti, F.; Bauvy, C.; Ventruti, A.; Sala, G.; Cluzeaud, F.; Vandewalle, A.; Ghidoni, R.; Codogno, P. Ceramide-mediated macroautophagy involves inhibition of protein kinase B and up-regulation of beclin 1. J. Biol. Chem. 2004, 279, 18384-18391.
171. Prinetti, A.; Basso, L.; Appierto, V.; Villani, M. G.; Valsecchi, M.; Loberto, N.; Prioni, S.; Chigorno, V.; Cavadini, E.; Formelli, F.; et al. Altered sphingolipid metabolism in N-(4-hydroxyphenyl)-retinamide-resistant A2780 human ovarian carcinoma cells. J. Biol. Chem. 2003, 278, 5574-5583.
172. Prinetti, A.; Millimaggi, D.; D'Ascenzo, S.; Clarkson, M.; Bettiga, A.; Chigorno, V.; Sonnino, S.; Pavan, A.; Dolo, V. Lack of ceramide generation and altered sphingolipid composition are associated with drug resistance in human ovarian carcinoma cells. Biochem. J. 2006, 395, 311-318.
173. Veldman, R. J.; Klappe, K.; Hinrichs, J.; Hummel, I.; van der Schaaf, G.; Sietsma, H.; Kok, J. W. Altered sphingolipid metabolism in multidrug-resistant ovarian cancer cells is due to uncoupling of glycolipid biosynthesis in the Golgi apparatus. FASEB J. 2002, 16, 1111-1113.
174. Dijkhuis, A. J.; Douwes, J.; Kamps, W.; Sietsma, H.; Kok, J. W. Differential expression of sphingolipids in P-glycoprotein or multidrug resistance-related protein 1 expressing human neuroblastoma cell lines. FEBS Lett. 2003, 548, 28-32.
175. Plo, I.; Lehne, G.; Beckstrom, K. J.; Maestre, N.; Bettaieb, A.; Laurent, G.; Lautier, D. Influence of ceramide metabolism on P-glycoprotein function in immature acute myeloid leukemia KG1a cells. Mol. Pharmacol. 2002, 62, 304-312.
176. Hakomori, S. I. Cell adhesion/recognition and signal transduction through glycosphingolipid microdomain. Glycoconj. J. 2000, 17, 143-151.
177. Anastasia, L.; Papini, N.; Colazzo, F.; Palazzolo, G.; Tringali, C.; Dileo, L.; Piccoli, M.; Conforti, E.; Sitzia, C.; Monti, E.; et al. NEU3 sialidase strictly modulates GM3 levels in skeletal myoblasts C2C12 thus favoring their differentiation and protecting them from apoptosis. J. Biol. Chem. 2008, 283, 36265-36271.
178. Kang, S. K.; Kim, Y. S.; Kong, Y. J.; Song, K. H.; Chang, Y. C.; Park, Y. G.; Ko, J. H.; Lee, Y. C.; Kim, C. H. isialoganglioside GD3 synthase expression recruits membrane transglutaminase 2 during erythroid differentiation of the human chronic myelogenous leukemia K562 cells. Proteomics 2008, 8, 3317-3328.
179. Hettmer, S.; McCarter, R.; Ladisch, S.; Kaucic, K. Alterations in neuroblastoma ganglioside synthesis by induction of GD1b synthase by retinoic acid. Br. J. Cancer 2004, 91, 389-397.
180. Nojiri, H.; Yamana, H.; Shirouzu, G.; Suzuki, T.; Isono, H. Glycotherapy for cancer: Remodeling of ganglioside pattern as an effective approach for cancer therapy. Cancer Detect. Prev. 2002, 26, 114-120.
181. Tringali, C.; Lupo, B.; Cirillo, F.; Papini, N.; Anastasia, L.; Lamorte, G.; Colombi, P.; Bresciani, R.; Monti, E.; Tettamanti, G.; et al. Silencing of membrane-associated sialidase Neu3 diminishes apoptosis resistance and triggers megakaryocytic differentiation of chronic myeloid leukemic cells K562 through the increase of ganglioside GM3. Cell Death Differ. 2009, 16, 164-174.
182. Guan, F.; Handa, K.; Hakomori, S. I. Specific glycosphingolipids mediate epithelial-to-mesenchymal transition of human and mouse epithelial cell lines. Proc. Natl. Acad. Sci. USA 2009, 106, 7461-7466.
183. Savagner, P. The epithelial-mesenchymal transition (EMT) phenomenon. Ann. Oncol. 2010, 21, vii89-vii92.
184. Min, Y.; Shi, J.; Zhang, Y.; Liu, S.; Liu, Y.; Zheng, D. Death receptor 5-recruited raft components contributes to the sensitivity of Jurkat leukemia cell lines to TRAIL-induced cell death. IUBMB Life 2009, 61, 261-267.
185. Falschlehner, C.; Emmerich, C. H.; Gerlach, B.; Walczak, H. TRAIL signalling: Decisions between life and death. Int. J. Biochem. Cell Biol. 2007, 39, 1462-1475.
186. Lim, S. C.; Duong, H. Q.; Choi, J. E.; Lee, T. B.; Kang, J. H.; Oh, S. H.; Han, S. I. Lipid raft-dependent death receptor 5 (DR5) expression and activation are critical for ursodeoxycholic acid-induced apoptosis in gastric cancer cells. Carcinogenesis 2011, 32, 723-731.
187. Ouyang, W.; Yang, C.; Zhang, S.; Liu, Y.; Yang, B.; Zhang, J.; Zhou, F.; Zhou, Y.; Xie, C. Absence of death receptor translocation into lipid rafts in acquired TRAIL-resistant NSCLC cells. Int. J. Oncol. 2013, 42, 699-711.
188. Xiao, W.; Ishdorj, G.; Sun, J.; Johnston, J. B.; Gibson, S. B. Death receptor 4 is preferentially recruited to lipid rafts in chronic lymphocytic leukemia cells contributing to tumor necrosis related apoptosis inducing ligand-induced synergistic apoptotic responses. Leuk. Lymphoma 2011, 52, 1290-1301.
189. Marconi, M.; Ascione, B.; Ciarlo, L.; Vona, R.; Garofalo, T.; Sorice, M.; Gianni, A. M.; Locatelli, S. L.; Carlo-Stella, C.; Malorni, W.; et al. Constitutive localization of DR4 in lipid rafts is mandatory for TRAIL-induced apoptosis in B-cell hematologic malignancies. Cell Death Dis. 2013, 4, e863.
190. Tringali, C.; Lupo, B.; Silvestri, I.; Papini, N.; Anastasia, L.; Tettamanti, G.; Venerando, B. The plasma membrane sialidase NEU3 regulates the malignancy of renal carcinoma cells by controlling β1 integrin internalization and recycling. J. Biol. Chem. 2012, 287, 42835-42845.
191. Dyatlovitskaya, E. V.; Bergelson, L. D. Glycosphingolipids and antitumor immunity. Biochim. Biophys. Acta 1987, 907, 125-143.
192. Fredman, P. Gangliosides associated with primary brain tumors and their expression in cell lines established from these tumors. Prog. Brain Res. 1994, 101, 225-240.
193. Berra, B.; Gaini, S. M.; Riboni, L. Correlation between ganglioside distribution and histological grading of human astrocytomas. Int. J. Cancer 1985, 36, 363-366.
194. Riboni, L.; Campanella, R.; Bassi, R.; Villani, R.; Gaini, S. M.; Martinelli-Boneschi, F.; Viani, P.; Tettamanti, G. Ceramide levels are inversely associated with malignant progression of human glial tumors. Glia 2002, 39, 105-113.
195. Malisan, F.; Testi, R. GD3 ganglioside and apoptosis. Biochim. Biophys. Acta 2002, 1585, 179-187.
196. Garcia-Ruiz, C.; Colell, A.; Paris, R.; Fernandez-Checa, J. C. Direct interaction of GD3 ganglioside with mitochondria generates reactive oxygen species followed by mitochondrial permeability transition, cytochrome c release, and caspase activation. FASEB J. 2000, 14, 847-858.
197. Kroemer, G.; Reed, J. C. Mitochondrial control of cell death. Nat. Med. 2000, 6, 513-519.
198. Rippo, M. R.; Malisan, F.; Ravagnan, L.; Tomassini, B.; Condo, I.; Costantini, P.; Susin, S. A.; Rufini, A.; Todaro, M.; Kroemer, G.; et al. GD3 ganglioside directly targets mitochondria in a bcl-2-controlled fashion. FASEB J. 2000, 14, 2047-2054.
199. De Maria, R.; Rippo, M. R.; Schuchman, E. H.; Testi, R. Acidic sphingomyelinase (ASM) is necessary for fas-induced GD3 ganglioside accumulation and efficient apoptosis of lymphoid cells. J. Exp. Med. 1998, 187, 897-902.
200. Colell, A.; Morales, A.; Fernandez-Checa, J. C.; Garcia-Ruiz, C. Ceramide generated by acidic sphingomyelinase contributes to tumor necrosis factor-α-mediated apoptosis in human colon HT-29 cells through glycosphingolipids formation. Possible role of ganglioside GD3. FEBS Lett. 2002, 526, 135-141.
201. Lovat, P. E.; di Sano, F.; Corazzari, M.; Fazi, B.; Donnorso, R. P.; Pearson, A. D.; Hall, A. G.; Redfern, C. P.; Piacentini, M. Gangliosides link the acidic sphingomyelinase-mediated induction of ceramide to 12-lipoxygenase-dependent apoptosis of neuroblastoma in response to fenretinide. J. Natl. Cancer Inst. 2004, 96, 1288-1299.
202. Birkle, S.; Zeng, G.; Gao, L.; Yu, R. K.; Aubry, J. Role of tumor-associated gangliosides in cancer progression. Biochimie 2003, 85, 455-463.
203. Koochekpour, S.; Merzak, A.; Pilkington, G. J. Vascular endothelial growth factor production is stimulated by gangliosides and TGF-β isoforms in human glioma cells in vitro. Cancer Lett. 1996, 102, 209-215.
204. Ziche, M.; Morbidelli, L.; Alessandri, G.; Gullino, P. M. Angiogenesis can be stimulated or repressed in vivo by a change in GM3: GD3 ganglioside ratio. Lab. Investig. 1992, 67, 711-715.
205. Zeng, G.; Gao, L.; Birkle, S.; Yu, R. K. Suppression of ganglioside GD3 expression in a rat F-11 tumor cell line reduces tumor growth, angiogenesis, and vascular endothelial growth factor production. Cancer Res. 2000, 60, 6670-6676.
206. Malisan, F.; Franchi, L.; Tomassini, B.; Ventura, N.; Condo, I.; Rippo, M. R.; Rufini, A.; Liberati, L.; Nachtigall, C.; Kniep, B.; et al. Acetylation suppresses the proapoptotic activity of GD3 ganglioside. J. Exp. Med. 2002, 196, 1535-1541.
207. Mukherjee, K.; Chava, A. K.; Mandal, C.; Dey, S. N.; Kniep, B.; Chandra, S.; Mandal, C. O-acetylation of GD3 prevents its apoptotic effect and promotes survival of lymphoblasts in childhood acute lymphoblastic leukaemia. J. Cell. Biochem. 2008, 105, 724-734.
208. Birks, S. M.; Danquah, J. O.; King, L.; Vlasak, R.; Gorecki, D. C.; Pilkington, G. J. Targeting the GD3 acetylation pathway selectively induces apoptosis in glioblastoma. Neuro-Oncol. 2011, 13, 950-960.
209. Mandal, C.; Tringali, C.; Mondal, S.; Anastasia, L.; Chandra, S.; Venerando, B.; Mandal, C. Down regulation of membrane-bound Neu3 constitutes a new potential marker for childhood acute lymphoblastic leukemia and induces apoptosis suppression of neoplastic cells. Int. J. Cancer J. Int. Cancer 2010, 126, 337-349.
210. Chen, H. Y.; Varki, A. O-acetylation of GD3: An enigmatic modification regulating apoptosis? J. Exp. Med. 2002, 196, 1529-1533.
211. Tomassini, B.; Malisan, F.; Franchi, L.; Nicolo, C.; Calvo, G. B.; Saito, T.; Testi, R. Calnexin suppresses GD3 synthase-induced apoptosis. FASEB J. 2004, 18, 1553-1555.
212. Malisan, F.; Testi, R. The ganglioside GD3 as the Greek goddess Hecate: Several faces turned towards as many directions. IUBMB Life 2005, 57, 477-482.
213. Watanabe, R.; Ohyama, C.; Aoki, H.; Takahashi, T.; Satoh, M.; Saito, S.; Hoshi, S.; Ishii, A.; Saito, M.; Arai, Y. Ganglioside G(M3) overexpression induces apoptosis and reduces malignant potential in murine bladder cancer. Cancer Res. 2002, 62, 3850-3854.
214. Noguchi, M.; Suzuki, T.; Kabayama, K.; Takahashi, H.; Chiba, H.; Shiratori, M.; Abe, S.; Watanabe, A.; Satoh, M.; Hasegawa, T.; et al. GM3 synthase gene is a novel biomarker for histological classification and drug sensitivity against epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Cancer Sci. 2007, 98, 1625-1632.
215. Kiura, K.; Watarai, S.; Ueoka, H.; Tabata, M.; Gemba, K.; Aoe, K.; Yamane, H.; Yasuda, T.; Harada, M. An alteration of ganglioside composition in cisplatin-resistant lung cancer cell line. Anticancer Res. 1998, 18, 2957-2960.
216. Uemura, S.; Kabayama, K.; Noguchi, M.; Igarashi, Y.; Inokuchi, J. Sialylation and sulfation of lactosylceramide distinctly regulate anchorage-independent growth, apoptosis, and gene expression in 3LL Lewis lung carcinoma cells. Glycobiology 2003, 13, 207-216.
217. Noguchi, M.; Kabayama, K.; Uemura, S.; Kang, B. W.; Saito, M.; Igarashi, Y.; Inokuchi, J. Endogenously produced ganglioside GM3 endows etoposide and doxorubicin resistance by up-regulating Bcl-2 expression in 3LL Lewis lung carcinoma cells. Glycobiology 2006, 16, 641-650.
218. Liu, J. W.; Sun, P.; Yan, Q.; Paller, A. S.; Gerami, P.; Ho, N.; Vashi, N.; le Poole, I. C.; Wang, X. Q. De-N-acetyl GM3 promotes melanoma cell migration and invasion through urokinase plasminogen activator receptor signaling-dependent MMP-2 activation. Cancer Res. 2009, 69, 8662-8669.
219. Blanco, R.; Rengifo, C. E.; Cedeno, M.; Frometa, M.; Rengifo, E.; Carr, A. Immunoreactivity of the 14F7 Mab (raised against N-glycolyl GM3 Ganglioside) as a positive prognostic factor in non-small-cell lung cancer. Pathol. Res. Int. 2012, 2012, 235418.
220. Blanco, R.; Rengifo, E.; Cedeno, M.; Rengifo, C. E.; Alonso, D. F.; Carr, A. Immunoreactivity of the 14F7 mab raised against N-glycolyl GM3 ganglioside in epithelial malignant tumors from digestive system. ISRN Gastroenterol. 2011, 2011, 645641.
221. Carr, A.; Mullet, A.; Mazorra, Z.; Vazquez, A. M.; Alfonso, M.; Mesa, C.; Rengifo, E.; Perez, R.; Fernandez, L. E. A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors. Hybridoma 2000, 19, 241-247.
222. Bremer, E. G.; Schlessinger, J.; Hakomori, S. Ganglioside-mediated modulation of cell growth. Specific effects of GM3 on tyrosine phosphorylation of the epidermal growth factor receptor. J. Biol. Chem. 1986, 261, 2434-2440.
223. Hayashi, N.; Chiba, H.; Kuronuma, K.; Go, S.; Hasegawa, Y.; Takahashi, M.; Gasa, S.; Watanabe, A.; Hasegawa, T.; Kuroki, Y.; et al. Detection of N-glycolyated gangliosides in non-small-cell lung cancer using GMR8 monoclonal antibody. Cancer Sci. 2013, 104, 43-47.
224. Hanai, N.; Dohi, T.; Nores, G. A.; Hakomori, S. A novel ganglioside, de-N-acetyl-GM3 (II3NeuNH2LacCer), acting as a strong promoter for epidermal growth factor receptor kinase and as a stimulator for cell growth. J. Biol. Chem. 1988, 263, 6296-6301.
225. Goel, S.; Hidalgo, M.; Perez-Soler, R. EGFR inhibitor-mediated apoptosis in solid tumors. J. Exp. Ther. Oncol. 2007, 6, 305-320.
226. Lingwood, C. A. Role of verotoxin receptors in pathogenesis. Trends Microbiol. 1996, 4, 147-153.
227. Wiels, J.; Fellous, M.; Tursz, T. Monoclonal antibody against a Burkitt lymphoma-associated antigen. Proc. Natl. Acad. Sci. USA 1981, 78, 6485-6488.
228. Distler, U.; Souady, J.; Hulsewig, M.; Drmic-Hofman, I.; Haier, J.; Friedrich, A. W.; Karch, H.; Senninger, N.; Dreisewerd, K.; Berkenkamp, S.; et al. Shiga toxin receptor Gb3Cer/CD77: Tumor-association and promising therapeutic target in pancreas and colon cancer. PLoS One 2009, 4, e6813.
229. Johansson, D.; Kosovac, E.; Moharer, J.; Ljuslinder, I.; Brannstrom, T.; Johansson, A.; Behnam-Motlagh, P. Expression of verotoxin-1 receptor Gb3 in breast cancer tissue and verotoxin-1 signal transduction to apoptosis. BMC Cancer 2009, 9, 67.
230. Liu, Y. Y.; Gupta, V.; Patwardhan, G. A.; Bhinge, K.; Zhao, Y.; Bao, J.; Mehendale, H.; Cabot, M. C.; Li, Y. T.; Jazwinski, S. M. Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and β-catenin signaling. Mol. Cancer 2010, 9, 145.
231. Willison, K. R.; Karol, R. A.; Suzuki, A.; Kundu, S. K.; Marcus, D. M. Neutral glycolipid antigens as developmental markers of mouse teratocarcinoma and early embryos: An immunologic and chemical analysis. J. Immunol. 1982, 129, 603-609.
232. Park, S. Y.; Kwak, C. Y.; Shayman, J. A.; Kim, J. H. Globoside promotes activation of ERK by interaction with the epidermal growth factor receptor. Biochim. Biophys. Acta 2012, 1820, 1141-1148.
233. Ruckhaberle, E.; Karn, T.; Rody, A.; Hanker, L.; Gatje, R.; Metzler, D.; Holtrich, U.; Kaufmann, M. Gene expression of ceramide kinase, galactosyl ceramide synthase and ganglioside GD3 synthase is associated with prognosis in breast cancer. J. Cancer Res. Clin. Oncol. 2009, 135, 1005-1013.
234. Ko, K.; Furukawa, K.; Takahashi, T.; Urano, T.; Sanai, Y.; Nagino, M.; Nimura, Y.; Furukawa, K. Fundamental study of small interfering RNAs for ganglioside GD3 synthase gene as a therapeutic target of lung cancers. Oncogene 2006, 25, 6924-6935.
235. Wada, T.; Hata, K.; Yamaguchi, K.; Shiozaki, K.; Koseki, K.; Moriya, S.; Miyagi, T. A crucial role of plasma membrane-associated sialidase in the survival of human cancer cells. Oncogene 2007, 26, 2483-2490.
236. Mikhaylova, O.; Stratton, Y.; Hall, D.; Kellner, E.; Ehmer, B.; Drew, A. F.; Gallo, C. A.; Plas, D. R.; Biesiada, J.; Meller, J.; et al. VHL-regulated MiR-204 suppresses tumor growth through inhibition of LC3B-mediated autophagy in renal clear cell carcinoma. Cancer Cell 2012, 21, 532-546.
237. Kakugawa, Y.; Wada, T.; Yamaguchi, K.; Yamanami, H.; Ouchi, K.; Sato, I.; Miyagi, T. Up-regulation of plasma membrane-associated ganglioside sialidase (Neu3) in human colon cancer and its involvement in apoptosis suppression. Proc. Natl. Acad. Sci. USA 2002, 99, 10718-10723.
238. Miyata, M.; Kambe, M.; Tajima, O.; Moriya, S.; Sawaki, H.; Hotta, H.; Kondo, Y.; Narimatsu, H.; Miyagi, T.; Furukawa, K.; et al. Membrane sialidase NEU3 is highly expressed in human melanoma cells promoting cell growth with minimal changes in the composition of gangliosides. Cancer Sci. 2011, 102, 2139-2149.
239. Kawamura, S.; Sato, I.; Wada, T.; Yamaguchi, K.; Li, Y.; Li, D.; Zhao, X.; Ueno, S.; Aoki, H.; Tochigi, T.; et al. Plasma membrane-associated sialidase (NEU3) regulates progression of prostate cancer to androgen-independent growth through modulation of androgen receptor signaling. Cell Death Differ. 2012, 19, 170-179.
240. Scaringi, R.; Piccoli, M.; Papini, N.; Cirillo, F.; Conforti, E.; Bergante, S.; Tringali, C.; Garatti, A.; Gelfi, C.; Venerando, B.; et al. NEU3 sialidase is activated under hypoxia and protects skeletal muscle cells from apoptosis through the activation of the epidermal growth factor receptor signaling pathway and the hypoxia-inducible factor (HIF)-1α. J. Biol. Chem. 2013, 288, 3153-3162.
241. Miyagi, T.; Wada, T.; Yamaguchi, K. Roles of plasma membrane-associated sialidase NEU3 in human cancers. Biochim. Biophys. Acta 2008, 1780, 532-537.
242. Yamaguchi, K.; Hata, K.; Koseki, K.; Shiozaki, K.; Akita, H.; Wada, T.; Moriya, S.; Miyagi, T. Evidence for mitochondrial localization of a novel human sialidase (NEU4). Biochem. J. 2005, 390, 85-93.
243. Basu, S.; Ma, R.; Mikulla, B.; Bradley, M.; Moulton, C.; Basu, M.; Banerjee, S.; Inokuchi, J. Apoptosis of human carcinoma cells in the presence of inhibitors of glycosphingolipid biosynthesis: I. Treatment of Colo-205 and SKBR3 cells with isomers of PDMP and PPMP. Glycoconj. J. 2004, 20, 157-168.
244. Chai, L.; McLaren, R. P.; Byrne, A.; Chuang, W. L.; Huang, Y.; Dufault, M. R.; Pacheco, J.; Madhiwalla, S.; Zhang, X.; Zhang, M.; et al. The chemosensitizing activity of inhibitors of glucosylceramide synthase is mediated primarily through modulation of P-gp function. Int. J. Oncol. 2011, 38, 701-711.
245. Sun, Y. L.; Zhou, G. Y.; Li, K. N.; Gao, P.; Zhang, Q. H.; Zhen, J. H.; Bai, Y. H.; Zhang, X. F. Suppression of glucosylceramide synthase by RNA interference reverses multidrug resistance in human breast cancer cells. Neoplasma 2006, 53, 1-8.
246. Maceyka, M.; Harikumar, K. B.; Milstien, S.; Spiegel, S. Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol. 2012, 22, 50-60.